Background In patients with cardiogenic shock the clinical treatment often involves
temporary mechanical circulatory support for initial haemodynamic stabilization to enable …

Background Acute decompensated heart failure (HF) and cardiogenic shock (CS) frequently
are refractory to conservative treatment and require mechanical circulatory support (MCS) …

Purpose Mortality from cardiogenic shock remains a significant clinical challenge. We report
our institutional experience with the Impella 5.0 as a means to improve survival and serve as …

We present the case of a 60-year-old gentleman who was admitted with acute-on-chronic
cardiogenic shock and was supported with axillary Impella 5.5® for 123 days prior to heart …

We report midterm results of Impella 5.5 use with focus placed on bridge-outcomes,
venoarterial extracorporeal membrane oxygenation (VA-ECMO) transition, complications …

We describe the use of an Impella 5.0 for mechanical support in acute cardiogenic shock
after an acute myocardial infarction. A 61-year-old man with a history of severe coronary …

Background: Despite historical differences in cardiogenic shock (CS) outcomes by etiology,
outcomes by CS etiology have yet to be described in patients supported by temporary …

Impella 5.0 and 5.5 constitute an efficient mechanical circulatory support (MCS) in patients
with cardiogenic shock (CS) or extremely decompensated heart failure. In addition to …

Background: Cardiogenic shock is associated with a mortality rate between 40-60%, and as
high as 70% in the setting of ST-elevation myocardial infarction. 1-5 In patients with …

OBJECTIVES Peripheral venoarterial extracorporeal life support (ECLS) for the treatment of
cardiogenic shock has shown to improve survival but is associated with complications …